SCH-202676: An allosteric modulator of both agonist and antagonist binding to G protein-coupled receptors; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 682802 |
| CHEMBL ID | 161867 |
| CHEMBL ID | 1188627 |
| SCHEMBL ID | 15521904 |
| SCHEMBL ID | 15521903 |
| SCHEMBL ID | 12305077 |
| MeSH ID | M0376718 |
| Synonym |
|---|
| smr001230740 |
| MLS002153327 , |
| OPREA1_002944 |
| NCGC00015951-01 |
| lopac-s-4063 |
| LOPAC0_001078 |
| sch-202676 |
| NCGC00015951-02 |
| NCGC00162335-01 |
| NCGC00015951-03 |
| NCGC00162335-02 |
| n-methyl-2,3-diphenyl-1,2,4-thiadiazol-5-imine |
| CHEMBL161867 , |
| NCGC00162335-03 |
| CHEMBL1188627 |
| CCG-205155 |
| methanamine, n-(2,3-diphenyl-1,2,4-thiadiazol-5(2h)-ylidene)- |
| SCHEMBL15521904 |
| SCHEMBL15521903 |
| bdbm60981 |
| cid_11957689 |
| (2,3-diphenyl-1,2,4-thiadiazol-5-ylidene)-methyl-amine;hydrobromide |
| n-methyl-2,3-diphenyl-1,2,4-thiadiazol-5-imine;hydrobromide |
| SCHEMBL12305077 |
| n-(2,3-diphenyl-[1,2,4]thiadiazole-5(2h)-ylidene)methanamine |
| BRD-K29562203-004-02-6 |
| (z)-n-(2,3-diphenyl-1,2,4- thiadiazol-5(2h)- ylidene)methanamine |
| us10208043, # 4 |
| bdbm350103 |
| SDCCGSBI-0051048.P002 |
| NCGC00015951-11 |
| NCGC00015951-08 |
| HY-133862 |
| CS-0134420 |
| PD054318 |
| AKOS040746332 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, HADH2 protein | Homo sapiens (human) | Potency | 3.2804 | 0.0251 | 20.2376 | 39.8107 | AID886; AID893 |
| Chain B, HADH2 protein | Homo sapiens (human) | Potency | 3.2804 | 0.0251 | 20.2376 | 39.8107 | AID886; AID893 |
| Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 4.4668 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 39.8107 | 0.0072 | 15.7588 | 89.3584 | AID411 |
| thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 21.1350 | 0.1000 | 20.8793 | 79.4328 | AID488773; AID588453 |
| 15-lipoxygenase, partial | Homo sapiens (human) | Potency | 0.7943 | 0.0126 | 10.6917 | 88.5700 | AID887 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 24.4914 | 0.0041 | 10.8903 | 31.5287 | AID493106; AID493107 |
| GLS protein | Homo sapiens (human) | Potency | 3.5481 | 0.3548 | 7.9355 | 39.8107 | AID624146 |
| TDP1 protein | Homo sapiens (human) | Potency | 4.4668 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| Thrombopoietin | Homo sapiens (human) | Potency | 2.5119 | 0.0251 | 7.3048 | 31.6228 | AID917; AID918 |
| DNA polymerase III, partial | Bacillus subtilis | Potency | 26.6795 | 1.0621 | 14.1528 | 26.6795 | AID485295 |
| hypothetical protein, conserved | Trypanosoma brucei | Potency | 8.4921 | 0.2239 | 11.2451 | 35.4813 | AID624147 |
| regulator of G-protein signaling 4 | Homo sapiens (human) | Potency | 10.7757 | 0.5318 | 15.4358 | 37.6858 | AID504845 |
| arylsulfatase A | Homo sapiens (human) | Potency | 0.9528 | 1.0691 | 13.9551 | 37.9330 | AID720538 |
| pyruvate kinase | Leishmania mexicana mexicana | Potency | 5.0119 | 0.3981 | 13.7447 | 31.6228 | AID945; AID959 |
| heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa) | Homo sapiens (human) | Potency | 32.8851 | 0.0165 | 25.3078 | 41.3999 | AID602332 |
| cytochrome P450 2D6 isoform 1 | Homo sapiens (human) | Potency | 31.6228 | 0.0020 | 7.5337 | 39.8107 | AID891 |
| cellular tumor antigen p53 isoform a | Homo sapiens (human) | Potency | 17.5595 | 0.3162 | 12.4435 | 31.6228 | AID902; AID924 |
| polyunsaturated fatty acid lipoxygenase ALOX12 | Homo sapiens (human) | Potency | 28.1838 | 1.0000 | 12.2326 | 31.6228 | AID1452 |
| cytochrome P450 2C19 precursor | Homo sapiens (human) | Potency | 3.1623 | 0.0025 | 5.8400 | 31.6228 | AID899 |
| cytochrome P450 2C9 precursor | Homo sapiens (human) | Potency | 1.9953 | 0.0063 | 6.9043 | 39.8107 | AID883 |
| D(1A) dopamine receptor | Homo sapiens (human) | Potency | 11.2202 | 0.0224 | 5.9449 | 22.3872 | AID488983 |
| atrial natriuretic peptide receptor 1 precursor | Homo sapiens (human) | Potency | 30.1313 | 0.1346 | 10.3950 | 30.1313 | AID1347049 |
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 35.0356 | 0.3548 | 28.0659 | 89.1251 | AID504847 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 9.8344 | 0.0060 | 26.1688 | 89.1251 | AID488953; AID540317 |
| atrial natriuretic peptide receptor 2 precursor | Homo sapiens (human) | Potency | 16.4816 | 0.0066 | 9.8094 | 18.4927 | AID1347050 |
| flap endonuclease 1 | Homo sapiens (human) | Potency | 100.0000 | 0.1337 | 25.4129 | 89.1251 | AID588795 |
| serine/threonine-protein kinase mTOR isoform 1 | Homo sapiens (human) | Potency | 26.1216 | 0.0037 | 8.6189 | 23.2809 | AID2660 |
| cytochrome P450 3A4 isoform 1 | Homo sapiens (human) | Potency | 31.6228 | 0.0316 | 10.2792 | 39.8107 | AID884; AID885 |
| M-phase phosphoprotein 8 | Homo sapiens (human) | Potency | 26.6795 | 0.1778 | 24.7352 | 79.4328 | AID488949 |
| histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 2.2387 | 0.2512 | 15.8432 | 39.8107 | AID504327 |
| muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | Potency | 8.8006 | 0.0010 | 6.0009 | 35.4813 | AID943; AID944 |
| pyruvate kinase PKM isoform b | Homo sapiens (human) | Potency | 25.1189 | 2.5119 | 12.2628 | 25.1189 | AID954; AID958 |
| Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) | Potency | 1.0000 | 0.3162 | 12.7657 | 31.6228 | AID881 |
| Integrin beta-3 | Homo sapiens (human) | Potency | 25.1189 | 0.3162 | 11.4157 | 31.6228 | AID924 |
| Integrin alpha-IIb | Homo sapiens (human) | Potency | 25.1189 | 0.3162 | 11.4157 | 31.6228 | AID924 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Alpha-synuclein | Homo sapiens (human) | Potency | 22.2719 | 0.5623 | 9.3985 | 25.1189 | AID652106 |
| Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | Potency | 1.5972 | 0.0063 | 8.2350 | 39.8107 | AID881; AID883 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| GABA theta subunit | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Ataxin-2 | Homo sapiens (human) | Potency | 25.1189 | 0.0119 | 12.2221 | 68.7989 | AID588378 |
| Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| 2,3-bisphosphoglycerate-independent phosphoglycerate mutase | Leishmania major strain Friedlin | Potency | 21.3313 | 7.5686 | 15.2306 | 21.3313 | AID504548 |
| ATP-dependent phosphofructokinase | Trypanosoma brucei brucei TREU927 | Potency | 10.6910 | 0.0601 | 10.7453 | 37.9330 | AID485368 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Replicase polyprotein 1ab | Betacoronavirus England 1 | IC50 (µMol) | 10.0000 | 0.0040 | 3.4388 | 9.5100 | AID1640022 |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | IC50 (µMol) | 0.9800 | 0.0002 | 2.4585 | 9.9600 | AID1640021 |
| Fascin | Homo sapiens (human) | IC50 (µMol) | 0.5000 | 0.5000 | 0.5000 | 0.5000 | AID1639641 |
| N-terminal Xaa-Pro-Lys N-methyltransferase 1 | Homo sapiens (human) | IC50 (µMol) | 0.4600 | 0.4600 | 0.4600 | 0.4600 | AID1864737 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| NPYLR7B | Aedes aegypti (yellow fever mosquito) | EC50 (µMol) | 20.0000 | 0.0390 | 2.2899 | 18.3000 | AID1259426 |
| Adenosine receptor A1 | Homo sapiens (human) | EC50 (µMol) | 2.8000 | 0.0001 | 0.9916 | 9.8000 | AID30292 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1864737 | Inhibition of full length His-NTMT1 (1 to 222 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) assessed as SAH production by Mtase-glo luminescence assay | 2022 | Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18 | Venglustat Inhibits Protein N-Terminal Methyltransferase 1 in a Substrate-Competitive Manner. |
| AID31101 | Dissociation constant for [3H]DPCPX binding to human adenosine A1 receptor plus or minus compound (10 uM); t1/2 = 6.61 min | 2004 | Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3 | Synthesis and biological evaluation of 2,3,5-substituted [1,2,4]thiadiazoles as allosteric modulators of adenosine receptors. |
| AID31097 | Association constant for [3H]DPCPX binding to human adenosine A1 receptor plus or minus compound (10 uM); appt1/2 = 3.85 min | 2004 | Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3 | Synthesis and biological evaluation of 2,3,5-substituted [1,2,4]thiadiazoles as allosteric modulators of adenosine receptors. |
| AID31088 | Percent remaining of radioligand [3H]DPCPX binding to human adenosine A1 receptor at 1 uM | 2004 | Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3 | Synthesis and biological evaluation of 2,3,5-substituted [1,2,4]thiadiazoles as allosteric modulators of adenosine receptors. |
| AID31089 | Percent remaining of radioligand [3H]DPCPX binding to human adenosine A1 receptor at 10 uM | 2004 | Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3 | Synthesis and biological evaluation of 2,3,5-substituted [1,2,4]thiadiazoles as allosteric modulators of adenosine receptors. |
| AID1074988 | Inhibition of human PPTase up to 125 uM by gel-based fluorescence assay | 2014 | Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3 | 4-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-methoxypyridin-2-yl)piperazine-1-carbothioamide (ML267), a potent inhibitor of bacterial phosphopantetheinyl transferase that attenuates secondary metabolism and thwarts bacterial growth. |
| AID31098 | Dissociation constant for [3H]-CCPA binding to human adenosine A1 receptor plus or minus compound (10 uM); t1/2 = 5.37 min | 2004 | Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3 | Synthesis and biological evaluation of 2,3,5-substituted [1,2,4]thiadiazoles as allosteric modulators of adenosine receptors. |
| AID31087 | Percent remaining of radioligand [3H]CCPA binding to human adenosine A1 receptor at 10 uM | 2004 | Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3 | Synthesis and biological evaluation of 2,3,5-substituted [1,2,4]thiadiazoles as allosteric modulators of adenosine receptors. |
| AID30292 | Effective concentration for displacement of [3H]-CCPA from human adenosine A1 receptor after 60 min | 2004 | Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3 | Synthesis and biological evaluation of 2,3,5-substituted [1,2,4]thiadiazoles as allosteric modulators of adenosine receptors. |
| AID1347059 | CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation | 2019 | PloS one, , Volume: 14, Issue:7 | Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors. |
| AID1347045 | Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line | 2019 | Science translational medicine, 07-10, Volume: 11, Issue:500 | Inhibition of natriuretic peptide receptor 1 reduces itch in mice. |
| AID504836 | Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation | 2002 | The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16 | Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID588349 | qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay | |||
| AID1347057 | CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation | 2019 | PloS one, , Volume: 14, Issue:7 | Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1347151 | Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID588378 | qHTS for Inhibitors of ATXN expression: Validation | |||
| AID1347049 | Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen | 2019 | Science translational medicine, 07-10, Volume: 11, Issue:500 | Inhibition of natriuretic peptide receptor 1 reduces itch in mice. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1347058 | CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation | 2019 | PloS one, , Volume: 14, Issue:7 | Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors. |
| AID1347050 | Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay | 2019 | Science translational medicine, 07-10, Volume: 11, Issue:500 | Inhibition of natriuretic peptide receptor 1 reduces itch in mice. |
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (45.00) | 29.6817 |
| 2010's | 6 (30.00) | 24.3611 |
| 2020's | 5 (25.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (16.64) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (5.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 19 (95.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||